BlackRock’s ABVC BioPharma ABVC Stock Holding History

BlackRock’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$54.8K	Hold	56,442	–	–	﹤0.01%	5104
2025 Q4	$120K	Hold	56,442	–	–	﹤0.01%	4855
2025 Q3	$172K	Buy	+56,442	New	+$173K	﹤0.01%	4710
2023 Q3	–	Sell	-581	Closed	-$3.02K	–	5447
2023 Q2	$3.02K	Sell	581 -3,684	-86%	-$24.5K	﹤0.01%	5348
2023 Q1	$27.3K	Buy	4,265 +144	+3%	+$1.03K	﹤0.01%	5215
2022 Q4	$25.8K	Buy	4,121 +254	+7%	+$1.88K	﹤0.01%	5346
2022 Q3	$34K	Sell	3,867 -37	-0.9%	-$311	﹤0.01%	5428
2022 Q2	$41K	Buy	+3,904	New	+$78.9K	﹤0.01%	5450

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

BlackRock's ABVC Position: Q1 2026 in Review

BlackRock held its ABVC BioPharma (ABVC) position steady in Q1 2026 at 56,442 shares worth $54.8K. The position accounts for ﹤0.01% of the portfolio, ranked #5104.

BlackRock first reported a position in ABVC in Q2 2022 and has held it in 8 quarters since. The position peaked at $172K in Q3 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

BlackRock held 56,442 shares of ABVC BioPharma worth $54.8K as of Q1 2026.
BlackRock left its ABVC BioPharma share count unchanged in Q1 2026.
ABVC BioPharma made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #5104 holding.
BlackRock first reported a position in ABVC BioPharma in Q2 2022 and has held it in 8 quarters since.
BlackRock's ABVC BioPharma position peaked at $172K in Q3 2025.
13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.